Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on January 4, 2021, the grant of 4,126 restricted stock units to six new employees under its 2019 Inducement Equity Plan, compliant with Nasdaq Listing Rule 5635(c)(4). This plan, adopted in November 2019, aims to provide compensation incentives to attract talent within the biopharmaceutical sector. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers with genetic drivers, boasting a pipeline of over 20 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has formed a three-year partnership with UC San Francisco (UCSF) to enhance the development of therapies for genetically driven diseases. This collaboration builds on a six-month pilot and aims to expedite the clinical translation of academic innovations into marketable treatments. BridgeBio intends to leverage UCSF's scientific expertise to efficiently bring new medicines to patients. Both organizations express enthusiasm about the partnership, emphasizing the importance of academia-industry collaborations in advancing medical research.
BridgeBio Pharma and Maze Therapeutics have launched a joint venture, Contour Therapeutics, aimed at advancing precision medicine for genetically defined cardiovascular diseases. This partnership leverages Maze's genetic drug discovery and BridgeBio's expertise in cardiac drug development. Initially, they will develop treatments for a specific genetically defined heart failure type. The collaboration builds on significant progress in targeting genetic causes of cardiovascular disease, aiming to innovate treatment approaches for this leading global health issue.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on December 1, 2020, the granting of stock options and restricted stock units to 15 new employees. A total of 15,351 stock options were granted at an exercise price of $51.13, along with 21,092 restricted stock units. This initiative was executed under the 2019 Inducement Equity Plan, aimed to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and has over 20 development programs in its pipeline.
BridgeBio Pharma has announced the FDA's acceptance of their New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor aimed at treating cholangiocarcinoma, a rare bile duct cancer. The NDA has been granted a Priority Review designation and is part of the Real-Time Oncology Review (RTOR) pilot program, expediting cancer treatments. This marks BridgeBio's second NDA acceptance, with plans for concurrent reviews in Australia and Canada through Project Orbis. Cholangiocarcinoma affects around 20,000 people annually in the U.S. and EU, with a low five-year survival rate of just 9%.
BridgeBio Pharma (Nasdaq: BBIO) and Navire Pharma have initiated a Phase 1 clinical trial for the SHP2 inhibitor BBP-398, targeting solid tumors with MAPK pathway mutations. The trial, led by MD Anderson’s David S. Hong, aims to evaluate safety and preliminary anti-tumor activity. The study consists of two parts, the first focusing on dose escalation to establish the recommended Phase 2 dose. BBP-398 emerged from collaborative research with MD Anderson, highlighting the potential of SHP2 inhibitors in treating hard-to-manage cancers.
BridgeBio Pharma (Nasdaq: BBIO) has executed a merger agreement with Eidos Therapeutics, aiming to enhance clinical and commercial capabilities for Eidos' acoramidis. The FDA accepted the New Drug Application for fosdenopterin for MoCD Type A under Priority Review. Financially, BridgeBio ended Q3 2020 with $710.7 million in cash and equivalents, a rise from $577.1 million at the end of 2019. However, operating expenses surged to $128.1 million for Q3 2020, up 58% from the previous year, resulting in a net loss of $130.2 million.
On November 1, 2020, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 9,566 shares to three new employees. This initiative is intended to incentivize the employees as they join the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock awards are part of BridgeBio's 2019 Inducement Equity Plan, established to reward individuals who contribute to the company's goals. Founded in 2015, BridgeBio focuses on developing treatments for genetic diseases and has over 20 programs in its pipeline.
BridgeBio Pharma (Nasdaq: BBIO) announced the initiation of a Phase 2 study for BBP-589, an investigational recombinant collagen 7 (rC7) therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic disorder. The trial is set to enroll six patients, assessing efficacy on wound healing and safety over 30 weeks. Previous Phase 1 results instill confidence in this potential therapy. BBP-589 has Orphan Drug Designation from the FDA and EMA, indicating promise for addressing unmet medical needs in rare diseases.
BridgeBio Pharma and the University of Colorado Anschutz Medical Campus announced a collaboration to advance research on genetically driven diseases into therapeutic applications. This expanded partnership follows an eight-month pilot collaboration, aiming to accelerate early-discovery research and commercialize promising therapies. The collaboration emphasizes a close partnership model between academia and the pharmaceutical industry, focusing on delivering breakthrough medicines for unmet patient needs. BridgeBio's pipeline includes over 20 development programs targeting Mendelian diseases and cancers with clear genetic drivers.